Made with FlowPaper - Flipbook Maker
THE 2023 IMPACT REPORTThis past year has been monumental for our cause. Several therapies targeting beta-amyloid have recently been shown to reduce the accumulation of plaques in the brain — a hallmark of Alzheimer’s disease. Advocates across the nation have pressed policymakers to take action, in state capitols and on Capitol Hill. It was also a year in which we grew the AIM Leadership Society and advanced policies to improve the lives of all those living with Alzheimer’s and other dementia. In this AIM Impact Report, we look back on these successes and preview how we will build on them in the coming years. A mother and son share how joining the AIM Leadership Society has allowed them to honor their loved ones, while growing closer. We also take a closer look at how AIM is supporting our most avid bipartisan congressional champions through the AIM Leadership Society, AIMPAC and allied events. You’ll learn how we’ve worked with these congressional champions to introduce and advance innovative new bills to change the way dementia care is delivered, support caregivers and improve clinical trial participation among underrepresented communities. And, you’ll read about how AIM is advancing policy changes nationwide. Plus, we say goodbye to one of the cause’s most ardent supporters — former Sen. Roy Blunt (R-Mo.). Finally, we look at the results of the 2022 midterm elections and preview how these results will impact how we’ll work with our champions to advance our mission. The policy successes we’ve achieved this last year — because of the work of our relentless advocates and partners like you — are making a difference for people impacted by this disease today. But our work is not done. Perhaps most notably, as new and better treatments addressing the underlying cause of Alzheimer’s disease receive Food and Drug Administration (FDA) approval, we must redouble our efforts to ensure Medicare and other insurers provide coverage for all who could benefit. Thank you for all you do to support our mission. We know you’ll continue to work hard with us in our efforts to achieve our vision of a world without Alzheimer’s and all other dementia. Joanne Pike, DrPH President and CEO, AIM Robert Egge Executive Director, AIM HELLO FRIENDS, Joanne Pike, DrPHRobert EggeAIM IMPACT REPORT 2023 ★ 1 2023 50 votes for majority 13 What the 2022 Election Results Mean for Alzheimer’s Policy 02 Teaming Up to Take On Alzheimer’s 04 Strengthening Our Nation’s Commitment to Fight Alzheimer’s 07 Recognizing an Alzheimer’s Champion 10 Growing Momentum in Congress 12 A Pipeline of Potential New Treatments Offers Hope for the Alzheimer’s Community Driving Change in States Across the Nation 08 16 Leadership Society 17 Board, Staff & Corporate PartnersTEAMING UP TO TAKE ON ALZHEIMER’S For Debbie Goodstein Rosenfeld and her son Zach Rosenfeld, joining the AIM Leadership Society has not only meant taking the next step in their advocacy fight, but getting involved has also enabled them to spend valuable time together supporting a cause near to both of their hearts. Like many of the members in the AIM Leadership Society, Debbie and Zach have been personally impacted by Alzheimer’s disease. Debbie’s mother is living with Alzheimer’s, and her father passed away from Alzheimer’s four years ago. Not long after her father’s diagnosis, Debbie got involved in the Alzheimer’s Association, joining the New York City Chapter Board of Directors, where she learned about additional ways to get involved. “I want to do as much as I possibly can, including getting Zach involved,” said Debbie. “I’ve seen the impact of the disease on my family. Seeing the stress and the impact on my mom, watching her lose her parents slowly…you just think of all the other families experiencing that, and you can’t help but feel inclined to act,” said Zach. Alzheimer’s disease impacts entire families, across multiple generations. For Debbie, the Leadership Society has been an opportunity for her to share her passion for philanthropy and spend more time with her son. “I thought the Leadership Society could be a way to get my kids involved because there’s so much discussion of policy and politics in my house. I thought this could be something we could share,” said Debbie. Only 24 years old, Zach is one of the youngest members of the Leadership Society. “I think it’s critical that the Leadership Society has representation from multiple generations,” said Debbie. “Whenever Zach shows up at one of these meetings, it makes an impact. I think people want to know that there’s multi-generational involvement. It helps move the needle.” Together, Debbie and Zach have attended the AIM Advocacy Forum in Washington, D.C., met with members of Congress, and participated in virtual briefings to stay up-to-date on the progress of AIM’s policy priorities. “One of my favorite things about the Advocacy Forum was having Zach there. We had such a good time together,” said Debbie. “Zach was so energized by it, and I’m so proud of him. I highly recommend this course of action to all parents out there looking to get involved and spend time with their kids.” Zach meets with Rep. Paul Tonko (D-NY) Debbie Goodstein Rosenfeld and Zach RosenfeldAIM IMPACT REPORT 2023 ★ 3 “Meeting with members of Congress, other Leadership Society members, attending the Advocacy Forum, all of those things evoke one thing for me: community. The Leadership Society has built a strong one,” said Zach. “I’m really proud to be a part of this community of people, from all across the country, all ages, all backgrounds, who are coming together for one common cause.” As the philanthropic foundation of AIM, Leadership Society members make an impact and move AIM’s priorities forward, ensuring that the issues of people living with dementia and their caregivers are heard clearly by members of Congress across both parties. “What stands out to me is those small intimate moments when you’re hearing people’s stories,” said Zach. “When you’re going around a table, sitting with other people with totally different backgrounds, with members of Congress, and in those moments we’re all the same. We’ve all had similar experiences, and we’re all committed to doing something about it.” Moments like these are made possible because of the support of Leadership Society members coming together and creating opportunities to directly engage with policy leaders. With dedicated Leadership Society members like Debbie and Zach, and advocates throughout the nation, the Alzheimer’s Association and AIM will continue advancing federal and state policies to overcome Alzheimer’s and all other dementia. ★ Debbie and Zach meeting with Rep. Barragán (D-Calif.) to discuss AIM’s policy priorities JOIN THE AIM LEADERSHIP SOCIETY 2023 MEMBERSHIP LEVELS $5,000+ Team 2025 $10,000+ Capitol Club $25,000+ Chairman’s Circle $50,000+ Leadership Council Hear more from Leadership Society members like Debbie and Zach about why they’re champions in the fight online at: alzimpact.org/Leadership_Society To become a member or learn more contact: Amy Newman 202.851.6775 anewman@alz-aim.org Throughout the 117th Congress, AIM’s nationwide network of advocates pushed a robust agenda to improve the lives of people impacted by Alzheimer’s and other dementia. AIM is leading the way to advance these policies, working with congressional champions on both sides of the aisle to develop and grow support for bipartisan legislation to address the Alzheimer’s crisis in our nation. “Thanks to our advocates and Leadership Society members from across the nation, we are making significant progress in securing research funding and improving care and support for individuals living with Alzheimer’s and their families. In the next Congress, we will continue working with our bipartisan congressional champions to build momentum and ensure our nation is taking action in the fight against Alzheimer’s and all other dementia,” said Rachel Conant, Alzheimer’s Association vice president of federal affairs and AIM vice president of political affairs. INVESTING IN ALZHEIMER’S RESEARCH AND THE PUBLIC HEALTH INFRASTRUCTURE In December 2022, Congress approved a $226 million increase for Alzheimer’s and dementia research funding at the National Institutes of Health (NIH), bringing annual funding to more than $3.7 billion for fiscal year 2023. With robust and steady investment, scientists will be able to work faster to advance basic disease knowledge, explore ways to reduce risk, uncover new biomarkers for early diagnosis and drug targeting, and develop potential treatments. Congress also funded the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act (P.L. 115-406) at $33 million. This law is working to implement effective Alzheimer’s intervention focused on public health issues such as increasing early detection and diagnosis, reducing risk, and preventing avoidable hospitalizations. ADVANCING EQUITY IN ALZHEIMER’S CLINICAL TRIALS Thanks to bipartisan support in Congress and record investment in research at the NIH, we’re making great progress in the fight against Alzheimer’s and other dementia. To ensure future treatments and means of prevention are effective in all populations, Alzheimer’s and other dementia research must be reflective of all Americans. That’s why the Alzheimer’s Association and AIM worked with bipartisan congressional champions to pass key provisions of the Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act (S. 1548 / H.R. 3085). Because of the support of our advocates across the nation and our bipartisan congressional champions, key provisions of the ENACT Act passed the House and Senate and were signed into law by President Biden in December 2022. STRENGTHENING OUR NATION’S COMMITMENT TO FIGHT ALZHEIMER’SAIM IMPACT REPORT 2023 ★ 5 “While tremendous progress is being made across the scientific community toward treatment, we must do more to ensure that no one is left behind, especially communities most affected by Alzheimer’s and dementia,” said Carl V. Hill, Ph.D., MPH, Alzheimer’s Association, chief diversity, equity and inclusion officer. “Yet too much of the Alzheimer’s research to date has not included sufficient numbers of Black, Hispanic, Asian or Native Americans to be representative of the U.S. population. Their participation and inclusion in clinical trials is essential to addressing the disparities in Alzheimer’s and other dementia. Together, we have worked to improve the recruitment, participation and retention of traditionally underrepresented groups in clinical trials by passing the ENACT Act.” Thanks to the hard work of our advocates and Leadership Society members, our nation has taken action to advance equity in Alzheimer’s research. RENEWING THE NATIONAL COMMITMENT TO ADDRESS THE ALZHEIMER’S CRISIS Since the 2011 passage of the National Alzheimer’s Project Act (NAPA) and the Alzheimer’s Accountability Act — two laws championed by the Alzheimer’s Association and AIM — congressional leaders have made addressing the Alzheimer’s crisis a national priority. Before the 2022 AIM Advocacy Forum, AIM worked with congressional leaders to build on the progress made over the last decade by developing and introducing the NAPA Reauthorization Act (S. 4203 / H.R. 7775) and the Alzheimer’s Accountability and Investment Act (S. 4202 / H.R. 7773), bipartisan legislation that will renew our nation’s commitment to the fight. In addition to reauthorizing NAPA, which is set to expire in 2025, the NAPA Reauthorization Act emphasizes the importance of healthy aging and risk reduction for Alzheimer’s disease. Additionally, the legislation underscores and addresses health disparities among underrepresented populations. The bipartisan Alzheimer’s Accountability and Investment Act would continue to prioritize Alzheimer’s and dementia research funding at the NIH. Since the Alzheimer’s Accountability Act was enacted, the federal investment in Alzheimer’s and dementia research funding has grown substantially. This bill will ensure Congress continues to hear directly from the scientists at the NIH through an annual Professional Judgment Budget. At the conclusion of the 117th Congress, thanks to the hard work of advocates, Leadership Society members and congressional champions, the NAPA Reauthorization Act had gained critical momentum, gaining support from 65 cosponsors in the House and 27 in the Senate, and the Alzheimer’s Accountability and Investment Act had reached 45 cosponsors in the House and 24 in the Senate. AIM will work with our bipartisan congressional champions to have these bills reintroduced in the 118th Congress. ALZHEIMER’S ACCOUNTABILITY AND INVESTMENT ACT COSPONSORS 24 SENATE Cosponsors 45 HOUSE Cosponsors NAPA REAUTHORIZATION ACT COSPONSORS 27 SENATE Cosponsors 65 HOUSE Cosponsors FORGING A PATH TO BETTER DEMENTIA CARE During the second half of the 117th Congress, AIM continued to grow momentum for the Comprehensive Care for Alzheimer’s Act . This bill would streamline today’s complicated health care maze for people living with dementia and their caregivers by addressing the way dementia care is delivered. The bill asks the Center for Medicare & Medicaid Innovation (CMMI) to test a different payment structure for dementia care management, which is a model of care that enables individuals with Alzheimer’s and their caregivers to more seamlessly navigate the health care and social support systems and to obtain more timely access to care. Dementia care management can reduce costs while improving the quality of care for those living with Alzheimer’s and other dementia. Thanks to AIM advocates and Leadership Society throughout the nation, there’s growing bipartisan support for this critical legislation in Congress with 134 cosponsors in the House and 39 in the Senate. AIM remains committed to reintroducing the Comprehensive Care for Alzheimer’s Act and growing bipartisan congressional support in the 118th Congress. ★ Read more about AIM’s federal policy priorities at: alzimpact.org/federal COMPREHENSIVE CARE FOR ALZHEIMER’S ACT COSPONSORS 39 SENATE Cosponsors 134 HOUSE Cosponsors $1.9B 2018 $2.3B 2019 $2.8B 2020 $3.1B 2021 $3.5B 2022 $3.7B 2023 $1.4B 2017 $986M 2016 $504M 2013 $562M 2014 Alzheimer’s Accountability Act 2025 Goal Set$503M 2012 Key provisions of the ENACT Act Medicare begins covering care planning for cognitive decline $631M 2015 1st 2020 Professional Judgement Budget (PJB) National Alzheimer’s Project Act 2011 $448M BOLD Infrastructure for Alzheimer's Act Reauthorization of the Older Americans Act Promoting Alzheimer's Awareness to Prevent Elder Abuse Act Improving HOPE for Alzheimer's Act MAKING PROGRESS IN THE FIGHT AGAINST ALZHEIMER’S AIM IMPACT REPORT 2023 ★ 7 RECOGNIZING AN ALZHEIMER’S CHAMPION Strong congressional champions have always been a key component of AIM’s success. Few congressional champions have had more of an impact than retiring Missouri Senator Roy Blunt (R). During his time in the Senate, Sen. Blunt was a steadfast supporter of the cause, especially during his time on the Senate Appropriations Subcommittee on Labor, Health, and Human Services. “Because of Senator Blunt’s strong leadership and tireless efforts, Alzheimer’s and dementia research funding has more than quintupled since he became the top Republican on the Labor/HHS Appropriations Subcommittee seven years ago. Our deepest gratitude goes to Senator Blunt for his unwavering dedication to the fight to end Alzheimer’s disease and all other dementia,” said Robert Egge, Alzheimer’s Association chief public policy officer and AIM executive director. During his time in office, Sen. Blunt helped advance legislation by cosponsoring bills including the HOPE for Alzheimer’s Act, the Improving HOPE for Alzheimer’s Act, the Younger Onset Alzheimer’s Disease Act, and the Palliative Care & Hospice Education and Training Act. In September 2022, the NIH honored Sen. Blunt by dedicating the Roy Blunt Center for Alzheimer’s and Related Dementias Building. This building is designed to be a beacon for global scientific talent and a catalyst for innovation in the field, where intramural NIH researchers work side-by-side with scientists from around the world to accelerate the translation of scientific findings into real-world applications. “Over the last decade, we have seen significant progress in the fight against Alzheimer’s because of congressional champions like Sen. Roy Blunt. He’s been a true partner to our cause and we’re appreciative of his lifetime of service to Missourians and the millions of Americans impacted by Alzheimer’s throughout the nation,” said Egge. At the 2022 AIM Advocacy Forum, Sen. Blunt was presented the Alzheimer’s Association Lifetime Leadership Award. AIM is committed to continuing to work with Alzheimer’s champions like Sen. Blunt on the state and federal levels in the years to come. Together with these leaders and volunteer advocates throughout the nation, the Alzheimer’s Association and AIM will keep up the fight against this devastating disease. ★ Sen. Blunt with Harry Johns and Joanne Pike, Dr.PH at the NIH building dedicationSen. Blunt receives the Alzheimer’s Association Lifetime Leadership AwardNext >